Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Thomas R. Jeffry
PET, Proteomics, and Immunophenotyping of Arterial Inflammation and Checkpoint Inhibition
Rankin, S. et al. (2026) PET, Proteomics, and Immunophenotyping of Arterial Inflammation and Checkpoint Inhibition. JAMA Cardiology, (doi: 10.1001/jamacardio.2026.3443) (PMID:42714919) (Early Online Publication) Text 390631.pdf - Accepted Version 399kB Abstract Importance: Immune checkpoint inhibitors (ICIs) have transformed cancer outcomes but may be associated with an increased risk of myocardial infarction and ischemic stroke.
Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework
Czajka-Francuz, P. et al. (2026) Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework. British Journal of Cancer, (doi: 10.1038/s41416-026-03543-6) (PMID:42493600) (Early Online Publication) Text 391839.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives.
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies
Sweis, R. F. et al. (2026) Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies. Journal for ImmunoTherapy of Cancer, 14(7), e014638. (doi: 10.1136/jitc-2025-014638) (PMID:42476725) Text 390851.pdf - Published Version Available under License Creative Commons Attribution Non-commercial.
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial
Sun, J.-M. et al. (2026) First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial. Lancet Oncology, 27(1), pp. 90-102. (doi: 10.1016/S1470-2045(25)00402-4) (PMID:41449151) Full text not currently available from Enlighten.
Improving surgical treatments for hepatocellular carcinoma
Malik, Abdullah K., Geh, Daniel, Evans, Thomas R. Jeffry ORCID: https://orcid.org/0000-0002-4175-914X, Chow, Pierce K.H., Mann, Derek A. and White, Steven A. (2025) Improving surgical treatments for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, (doi: 10.1038/s41575-025-01143-y) (PMID:41249657) (Early Online Publication) Full text not currently available from Enlighten. Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide.
Prospective evaluation of the cardiovascular effects of BRAF and MEK inhibitors in patients with melanoma
Glen, C. et al. (2025) Prospective evaluation of the cardiovascular effects of BRAF and MEK inhibitors in patients with melanoma. JACC: CardioOncology, (Accepted for Publication) Text 363238.pdf - Accepted Version Restricted to Repository staff only 454kB Articles NNL and CG are supported by a restricted grant from Roche Diagnostics, Switzerland. NNL and MCP are supported by a British Heart Foundation Centre of Research Excellence Grant (RE/18/6/34217).
Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the west of Scotland: a cohort study
McLaren, A. S. et al. (2023) Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the west of Scotland: a cohort study. BMJ Open Gastroenterology, 10(1), e001231. (doi: 10.1136/bmjgast-2023-001231) (PMID:37989352) (PMCID:PMC10660158) Text 309027.pdf - Published Version Available under License Creative Commons Attribution.
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study
Solovyeva, O. et al. (2023) Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study. BMC Medicine, 21, 246. (doi: 10.1186/s12916-023-02937-0) Text 302304.pdf - Published Version Available under License Creative Commons Attribution. 1MB Abstract Background: Early phase dose-finding (EPDF) trials are crucial for the development of a new intervention and influence whether it should be investigated in further trials.
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
Hamid, O. et al. (2023) Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. Journal for ImmunoTherapy of Cancer, 11(6), e006747. (doi: 10.1136/jitc-2023-006747) (PMID:37286303) (PMCID:PMC10254987) Text 300986.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. 3MB Abstract Background: Immune checkpoint inhibitors have significantly improved outcomes in first line cutaneous melanoma.
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
British Journal of Cancer, May 2023 This is a preview of a remote PDF: https://www.nature.com/articles/s41416-023-02279-x.pdf Kristeleit, Rebecca, Plummer, Ruth, Jones, Robert, Carter, Louise, Blagden, Sarah, Sarker, Debashis, Arkenau, Tobias, Evans, Thomas R. Jeffry, Danson, Sarah, Symeonides, Stefan N., Veal, Gareth J., Klencke, Barbara J., Kowalski, Mark M., Banerji, Udai. , British Journal of Cancer, DOI: 10.1038/s41416-023-02279-x
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
Kristeleit, R. et al. (2023) A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer, 129(1), pp. 38-45. (doi: 10.1038/s41416-023-02279-x) (PMID:37120671) (PMCID:PMC10307885) Text 298383.pdf - Published Version Available under License Creative Commons Attribution. 891kB Abstract Background: This was a first-in-human Phase 1/2 open-label dose-escalation study of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737.
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study - BMC Medicine
Timeline and key parts of the study To drive delivery of the project, an international Executive Committee (EC) of multidisciplinary experts was formed, and an Independent Expert Panel (IEP) provided oversight and quality control assurances (see Additional file A1). Development of CONSORT-DEFINE commenced in March 2021, followed by SPIRIT-DEFINE in January 2022.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Thomas R.
Contact Thomas R., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack